Tender detail
Conclusion of a non-exclusive rebate agreement for dydrogesterone-containing medicines
Summary
The tender concerns the conclusion of non-exclusive pharmaceutical rebate agreements for medicines containing dydrogesterone (ATC G03DB01). The agreements are intended to run from 1 October 2026 to 30 September 2028, with a possible 12-month extension, and may be concluded with all interested pharmaceutical companies that meet the requirements. The agreements will end automatically when an exclusive agreement for the same active substance enters into force.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.